LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.23 2.87

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.13

Max

3.3

Pagrindiniai rodikliai
By Trading Economics
Pajamos	8.3M -18M
Pardavimai	9.6M 10M
P/E Sektoriaus vid.	22.5 49.888
Pelnas, tenkantis vienai akcijai	-0.1
Pelno marža	-177.89
Darbuotojai	69
EBITDA	8M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+289.24% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-159M 751M
Ankstesnė atidarymo kaina	0.36
Ankstesnė uždarymo kaina	3.23

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-03 23:22; UTC

Uždarbis

Pagrindinės rinkos jėgos

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

2026-06-03 23:09; UTC

Karštos akcijos

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

2026-06-03 20:51; UTC

Uždarbis

Costco Reports 15% Sales Growth in May

2026-06-03 20:43; UTC

Uždarbis

Broadcom 2Q Revenue Climbs on AI Chip Demand

2026-06-03 23:48; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

2026-06-03 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-03 23:35; UTC

Rinkos pokalbiai

Oil Futures Fall on Possible Technical Correction -- Market Talk

2026-06-03 23:15; UTC

Rinkos pokalbiai

Uždarbis

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

2026-06-03 22:08; UTC

Karštos akcijos

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

2026-06-03 21:54; UTC

Rinkos pokalbiai

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

2026-06-03 21:18; UTC

Uždarbis

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

2026-06-03 21:15; UTC

Uždarbis

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

2026-06-03 21:13; UTC

Uždarbis

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

2026-06-03 21:13; UTC

Uždarbis

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

2026-06-03 21:12; UTC

Uždarbis

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

2026-06-03 21:09; UTC

Uždarbis

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

2026-06-03 21:03; UTC

Uždarbis

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

2026-06-03 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-03 20:43; UTC

Uždarbis

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

2026-06-03 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

2026-06-03 20:37; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

2026-06-03 20:35; UTC

Uždarbis

Broadcom Stock Falls Despite Record Results -- Barrons.com

2026-06-03 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

2026-06-03 20:17; UTC

Uždarbis

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

2026-06-03 20:17; UTC

Uždarbis

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

2026-06-03 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Adj EPS $2.44 >AVGO

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q EPS $1.91 >AVGO

2026-06-03 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Rev $22.19B >AVGO

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

289.24% į viršų

12 mėnesių prognozė

Vidutinis 12.3 USD 289.24%

Aukščiausias 16 USD

Žemiausias 6 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.